Similar articles

Abstract: Objective: The efflux pump (EP) is one of the major mechanisms of antibiotic resistance in Klebsiella pneumoniae. However, there are few reports on the effect of the abuse of antibiotic use on the activity of EPs. To determine whether the use of low efficacy antibiotics has any effect on the activity of EPs and induces drug resistance in K. pneumoniae, we investigated the effect of ciprofloxacin on the activity of EPs in K. pneumoniae strains. Methods: Sixteen susceptible K. pneumoniae strains were isolated from patients and their minimum inhibitory concentrations (MICs) of ciprofloxacin were measured in the absence and presence of the pump inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP). The strains were then induced with a gradient of ciprofloxacin until the MICs of the strains showed no further increase, to obtain induced resistant strains. The EP activities of the strains before and after induction were compared using EP inhibition and ethidium bromide (EtBr) accumulation assays. Results: The MIC values of the strains were 16‒256 times higher after induction than before induction. In the presence of CCCP, the MIC values of 50% of the induced strains were 2‒4-fold lower than that in the absence of this inhibitor. The EtBr accumulation assay showed that the fluorescence of EtBr in the induced cells was lower than that in the cells before induction. Conclusions: EPs are widespread in susceptible and drug-resistant K. pneumoniae strains. Induction with ciprofloxacin may increase the activity of EPs in K. pneumoniae. The EtBr accumulation assay is more sensitive than the EP inhibition assay in evaluating the activity of EPs in K. pneumoniae.

[1]Aathithan, S., French, G.L., 2011. Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis., 30(6):745-752.

[2]Chollet, R., Chevalier, J., Bryskier, A., Pagès, J.M., 2004. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob. Agents Chemother., 48(9):3621-3624.

[3]CLSI (Clinical and Laboratory Standards Institute), 2012. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-second Informational Supplement. ISO M100-S22:2012, Clinical and Laboratory Standards Institute, America.

[4]Daugelavičius, R., Buivydas, A., Senčilo, A., Bamford, D.H., 2010. Assessment of the activity of RND-type multidrug efflux pumps in Pseudomonasaeruginosa using tetraphenylphosphonium ions. Int. J. Antimicrob. Agents, 36(3):234-238.

[5]Echeverri-Toro, L.M., Rueda, Z.V., Maya, W., Agudelo, Y., Ospina, S., 2012. Multidrug-resistant Klebsiella pneumoniae, predisposing factors and associated mortality in a tertiary-care hospital in Colombia. Rev. Chilena Infectol., 29(2):175-182.

[6]Falagas, M.E., Karageorgopoulos, D.E., 2009. Extended-spectrum β-lactamase-producing organisms. J. Hosp. Infect., 73(4):345-354.

[7]Hasdemir, U.O., Chevalier, J., Nordmann, P., Pagès, J.M., 2004. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J. Clin. Microbiol., 42(6):2701-2706.

[8]Hopkins, K.L., Davies, R.H., Threlfall, E.J., 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int. J. Antimicrob. Agents, 25(5):358-373.

[9]Kumar, A., Mayo, M., Trunck, L.A., Cheng, A.C., Currie, B.J., Schweizer, H.P., 2008. Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia. Trans. R. Soc. Trop. Med. Hyg., 102:S145-S151.

[10]Li, X.Z., Nikaido, H., 2009. Efflux-mediated drug resistance in bacteria: an update. Drugs, 69(12):1555-1623.

[11]Lynch, A.S., 2006. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem. Pharmacol., 71(7):949-956.

[12]Nikaido, H., 2001. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin. Cell Dev. Biol., 12(3):215-223.

[13]Pagès, J.M., Amaral, L., 2009. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta, 1794(5):826-833.

[14]Paixão, L., Rodrigues, L., Couto, I., Martins, M., Fernandes, P., de Carvalho, C.C., Monteiro, G.A., Sansonetty, F., Amaral, L., Viveiros, M., 2009. Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J. Biol. Eng., 3(1):18.

[15]Rodríguez-Martínez, J.M., Cano, M.E., Velasco, C., Martínez-Martínez, L., Pascual, A., 2011. Plamid-mediated quinolone resistance: an update. J. Infect. Chemother., 17(2):149-182.

[16]Schito, G.C., Naber, K.G., Botto, H., Palou, J., Mazzei, T., Gualco, L., Marchese, A., 2009. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents, 34(5):407-413.

[17]van Bambeke, F., Balzi, E., Tulkens, P.M., 2000. Antibiotic efflux pumps. Biochem. Pharmacol., 60(4):457-470.

[18]van der Donk, C.F., Beisser, P.S., Hoogkamp-Korstanje, J.A., Bruggeman, C.A., Stobberingh, E.E., Antibotic Resistance Surveillance Group, 2011. A 12-year (1998‒2009) antibiotic resistance surveillance of Klebsiella pneumoniae collected from intensive care and urology patients in 14 Dutch hospitals. J. Antimicrob. Chemother., 66(4):855-858.